Up to 39% more definitive results3

MammaPrint stratifies patients into two distinct groups, Low Risk and High Risk of breast cancer recurrence within 10 years.  This binary classification provides up to 39% more definitive results, as compared to other assays that have an intermediate, or undetermined result which can affect up to 39% of patients tested.